10-K: SANUWAVE Health Reports Strong 2025 Growth, Net Income Turnaround

SANUWAVE Health, Inc. announced a significant financial turnaround in its 2025 annual report, achieving net income and substantial revenue growth following a debt refinancing and prior period restatements.

Summary

• Total revenues for the year ended December 31, 2025, increased by 35% to $44.1 million, up from $32.6 million in 2024.
• The company reported a net income of $11.8 million, or $1.38 per basic share and $0.41 per diluted share, for 2025, a significant improvement from a net loss of $33.1 million in 2024 (as restated).
• Operating income grew by 29% to $4.9 million in 2025, compared to $3.8 million in 2024.
• Gross margin improved to 77% in 2025 from 75% in 2024, driven by increased pricing on UltraMIST consumables and reductions in system cost of revenue.
• Sales volumes for UltraMIST consumables increased by 24%, and UltraMIST systems sold increased by 67% in 2025 compared to 2024.
• The company successfully refinanced its secured debt in 2025 with a new $23.0 million secured term loan and a $5.0 million secured revolving credit facility, extending debt maturities and alleviating prior going concern doubts.
• A restatement of previously issued financial statements for 2024 and the first three quarters of 2025 was necessary due to an understatement of sales tax liabilities and an overstatement of extended warranty revenue.
• As of December 31, 2025, there were 1,292 active UltraMIST systems in the field.
• The company identified material weaknesses in its internal control over financial reporting, which were not remediated as of December 31, 2025.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this filing positively due to the significant financial turnaround, strong revenue growth, and successful debt refinancing. However, the identified material weaknesses in internal controls and the need for prior period restatements introduce a degree of caution.

Positives

• Net income dramatically improved to $11.8 million in 2025 from a $33.1 million net loss in 2024 (as restated), representing a $44.9 million increase.
• Revenue increased by 35% to $44.1 million in 2025, driven by strong sales volumes for UltraMIST consumables (+24%) and systems (+67%).
• Operating income grew by 29% to $4.9 million in 2025, demonstrating a focus on profitable growth.
• Gross margin improved to 77% in 2025 from 75% in 2024, indicating better cost management and pricing strategies.
• Successful refinancing of secured debt in 2025 extended maturities and provided additional liquidity, alleviating prior substantial doubt about the company's ability to continue as a going concern.
• The company received a one-time payment of $5.0 million in 2025 from the exercise of a patent acquisition option, contributing to other income.
• Cash flows provided by operating activities increased to $3.9 million in 2025 from $2.5 million in 2024.

Negatives

• The company identified material weaknesses in its internal control over financial reporting, which were not remediated as of December 31, 2025, posing a risk for future financial reporting accuracy.
• A restatement of prior period financial statements (2024 and Q1-Q3 2025) was required due to an understatement of sales tax liabilities and an overstatement of extended warranty revenue, indicating past accounting errors.
• General and administrative expenses increased by 50% to $19.4 million in 2025, primarily due to increased headcount, stock-based compensation, and professional fees.
• The average selling price of UltraMIST systems declined by 3% in 2025, primarily due to a higher proportion of sales through resellers.
• The company's ability to utilize net operating loss carryforwards (NOLs) is limited, with $44.2 million of NOL tax attributes expected to expire unutilized due to ownership shifts.

Risks

• Material weaknesses in internal control over financial reporting could lead to material misstatements or failure to meet periodic reporting obligations.
• The ability to utilize net operating loss carryforwards and certain other tax attributes may be limited by Section 382 of the Internal Revenue Code.
• Inability to successfully raise additional capital could threaten viability, and future financings could result in substantial dilution to stockholders or impose operational restrictions.
• The medical device/therapeutic product industries are highly competitive and subject to rapid technological change, potentially reducing or eliminating commercial opportunities.
• Changes in reimbursement affecting the wound care market could adversely affect customers and indirectly reduce demand for products.
• Dependence on single suppliers for many product component materials could disrupt production if suppliers encounter problems or are lost.
• Loss of key management or inability to attract and retain highly qualified personnel could hinder the ability to execute the business plan.
• Inherent risk of liability if the use or misuse of products results in personal injury or death, with insurance coverage potentially insufficient.
• Reliance on information technology systems and infrastructure faces risks from cybersecurity breaches and data leakage, which could negatively impact operations.
• Inability to expand, manage, and maintain direct sales and marketing organizations may prevent generation of anticipated revenue.
• Failure to properly manage growth effectively could strain personnel, information technology systems, and other resources.
• International activities are subject to various risks, including compliance with foreign regulations, political/economic instability, and difficulties protecting intellectual property.
• Provisions in the Articles of Incorporation, Bylaws, and Nevada law might decrease the chances of an acquisition.
• Extensive governmental regulation by the FDA and other countries, with failure to comply resulting in fines, product recalls, or criminal prosecutions.
• Regulatory approval of products may be withdrawn at any time.
• Failure to obtain an adequate level of reimbursement for approved products by third-party payors could limit market viability.
• Failure to obtain regulatory approval in foreign jurisdictions will prevent marketing products abroad.
• Uncertainty surrounding and future changes to healthcare law in the United States may have a material adverse effect.
• Failure to comply with the United States Federal Anti-Kickback Statute, False Claims Act, and similar state laws could lead to criminal and civil penalties.
• Failure to comply with HIPAA and state-specific privacy laws may increase operational costs.
• Periodic reviews and billing audits from governmental and private payors could result in adverse outcomes.
• Product quality or performance issues may be discovered through ongoing regulation or internal processes.
• The use of hazardous materials in operations may subject the company to environmental claims or liability.
• Failure to adequately protect intellectual property rights (patents, trade secrets) could materially adversely affect the business.
• Patent applications may not result in issued patents, or competitors may commercialize discoveries.
• Issued patents may not be valid or enforceable and may be challenged by third parties.
• Issued patents and patent licenses may not provide competitive advantage or meaningful protection.
• The ability to market products is subject to the intellectual property rights of third parties, potentially leading to costly litigation.
• The company's stock price is volatile and could fluctuate widely due to various factors.

Future Outlook

Management believes that anticipated cash flows from operations and cash on hand will be sufficient to satisfy working capital needs, capital expenditures, and debt repayments for at least the next twelve months. The company aims to continue building its direct sales force and distribution network for UltraMIST in the U.S. and assess international expansion. It expects continued market adoption driven by a transition to evidence-based medicine and 'care to the edge' trends, with UltraMIST consumables remaining the largest revenue stream. The company plans to further strengthen its internal control environment by adding personnel, improving segregation of duties, and enhancing information technology general controls.

Management Comments

• Management executed a comprehensive refinancing of the company's secured debt with a new lender, which extended the maturity of the company's principal debt obligations and established a secured revolving credit facility.
• Management believes that anticipated cash flows from operations, and cash on hand will be sufficient to satisfy our working capital needs, capital expenditures and debt repayments for at least twelve months from the issuance date of these consolidated financial statements.
• Management remains focused on maintaining the company's improved financial position and operational momentum.
• We are confident that the steps taken to date position the Company well to support ongoing operations and execute on our strategic objectives.

Industry Context

StockSavvy.ai notes that SANUWAVE Health's strong revenue growth and shift to profitability align with the broader trend of increasing demand for advanced wound care solutions, particularly non-invasive, effective, and patient-friendly technologies. The company's focus on the UltraMIST system, which offers non-contact, pain-free treatment with established CMS reimbursement, positions it well within the industry's move towards evidence-based medicine and 'care to the edge' models that prioritize cost-effectiveness and patient convenience outside traditional hospital settings. The estimated $67+ billion U.S. wound care market, driven by an aging population and rising chronic diseases, provides a substantial growth runway for companies with innovative solutions like UltraMIST.

Comparison to Industry Standards

• SANUWAVE's UltraMIST system competes with a broad range of advanced wound care technologies from multinational medical device companies such as Solventum, Smith & Nephew, Molnlycke Health Care, Essity, Coloplast, and Convatec, which offer extensive portfolios of wound dressings and negative pressure wound therapy systems.
• In the cellular and tissue-based product segment, competitors include Organogenesis, MiMedx Group, Integra LifeSciences, Vericel, and Kerecis, which often involve more complex and costly interventions compared to UltraMIST's non-contact ultrasound approach.
• Direct energy-based wound treatment competitors include ultrasound systems from Arobella Medical and NanoVibronix, and acoustic wave technologies from SoftWave Tissue Regeneration Technologies. UltraMIST differentiates itself with its low-frequency, non-thermal, non-contact application, which the company believes offers advantages in ease of use and patient tolerability.
• The company's 77% gross margin in 2025 is generally strong for a medical device company, indicating efficient production and pricing power, potentially outperforming some competitors heavily reliant on commodity-like wound dressings.
• The significant turnaround from a net loss to net income in 2025, coupled with debt refinancing, suggests a stronger financial footing compared to many smaller, earlier-stage medical device companies that often struggle with sustained profitability and capital access.

Management Changes

Corporate Governance

Legal Proceedings

• No material pending legal proceedings are believed to have a material adverse effect on the company's business, financial position, results of operations, or cash flows.
• The Agreement and Plan of Merger with SEP Acquisition Corp. was terminated in June 2024.
• An acquisition dispute with Celularity Inc. was settled in June 2024 for a cash payment of $2.2 million, resulting in a $5.3 million gain on extinguishment of debt.

Related Party Transactions

• In June 2024, the company entered into a $0.5 million promissory note with a related party, which was paid in full with accrued interest in October 2024.
• A convertible promissory note payable to a related party, issued in August 2020 for $1.4 million, was settled in 2024 for a cash payment of $1.4 million, resulting in a gain on extinguishment of debt of $0.8 million.

Stakeholder Impact

• Shareholders: Experienced significant dilution from past capital raises and conversions, and face potential future dilution. The stock price is volatile, and no dividends are anticipated. However, the company's return to profitability and debt refinancing are positive for shareholder value.
• Employees: The company had 55 full-time employees as of December 31, 2025, with increased headcount expenses. The 2024 Equity Incentive Plan provides incentives, but the material weaknesses in internal controls could impact employee confidence and operational efficiency.
• Customers: Benefit from the UltraMIST system's effectiveness, ease of use, and pain-free treatment for chronic wounds. Continued product development and market expansion aim to improve patient outcomes and access to care.
• Suppliers: The company relies on single suppliers for many product components, posing a risk of disruption if supplier relationships are impacted.
• Creditors: The successful refinancing of secured debt with JPMorgan Chase Bank, N.A. has improved the company's financial stability and ability to meet its obligations, reducing risk for creditors.

Next Steps

• Continue to build a direct sales force and distribution network to market the UltraMIST product in the United States.
• Assess potential expansion of UltraMIST abroad.
• Monitor financial position, operating results, and compliance with debt covenants on an ongoing basis.
• Evaluate opportunities to further enhance the capital structure and support growth strategy.
• Remediate identified material weaknesses in internal control over financial reporting by enhancing technical accounting resources, formalizing internal control procedures, and improving oversight and documentation.
• Conduct annual surveillance audits in 2026 to maintain MDSAP certification.

Key Dates

Recommendation

SANUWAVE Health's 2025 results demonstrate a significant operational and financial turnaround, marked by robust revenue growth, a return to net profitability, and successful debt refinancing. These factors, combined with the alleviation of going concern doubts and a strong gross margin, indicate a positive trajectory. While the restatement and ongoing material weaknesses in internal controls are notable, management is actively addressing these issues. For a seasoned investor, the strong underlying business performance, market opportunity in wound care, and improved financial health present a compelling 'buy' opportunity, albeit with an understanding of the inherent risks in a competitive and regulated medical device sector.

Keywords

Wound Care, Medical Device, UltraMIST, Ultrasound Therapy, Regenerative Medicine, SEC Filing, 10-K, Financial Results, Debt Refinancing, Restatement, SNWV, FDA Cleared, CMS Reimbursement, Intellectual Property